Cargando…

Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies

OBJECTIVE: The optimal sequencing of targeted therapies for metastatic renal cell carcinoma (mRCC) is unknown. Observational studies with a variety of designs have reported differing results. The objective of this study is to systematically summarize and interpret the published real-world evidence c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heng, Daniel Y., Signorovitch, James, Swallow, Elyse, Li, Nanxin, Zhong, Yichen, Qin, Paige, Zhuo, Daisy Y., Wang, Xufang, Park, Jinhee, Stergiopoulos, Sotirios, Kollmannsberger, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262396/ https://www.ncbi.nlm.nih.gov/pubmed/25493562 http://dx.doi.org/10.1371/journal.pone.0114264

Ejemplares similares

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment
por: Sweet, Donna, et al.
Publicado: (2014)

Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey
por: Lin, Peggy L., et al.
Publicado: (2015)

State-of-the-art treatment of metastatic renal cell carcinoma
por: Heng, D.Y.C., et al.
Publicado: (2009)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
por: King, Gentry, et al.
Publicado: (2022)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
por: Koutsoukos, Konstantinos, et al.
Publicado: (2017)

Real‐world outcomes among patients with advanced or metastatic biliary tract cancers initiating second‐line treatment
por: Cosgrove, David P., et al.
Publicado: (2022)

Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
por: Swallow, Elyse, et al.
Publicado: (2017)

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
por: Swallow, Elyse, et al.
Publicado: (2018)

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
por: Gómez-Ulloa, David, et al.
Publicado: (2020)

Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2016)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data
por: Vogelzang, Nicholas J., et al.
Publicado: (2018)

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
por: Mercuri, Eugenio, et al.
Publicado: (2016)

Corrigendum to “Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy” [Neuromuscular Disorders 26/9 (2016) 576–583]
por: Mercuri, Eugenio, et al.
Publicado: (2017)

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
por: Becker, Jürgen C., et al.
Publicado: (2017)

Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
por: Abraham, Pranav, et al.
Publicado: (2020)

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
por: Dai, Wei Fang, et al.
Publicado: (2020)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
por: Fernández Montes, Ana, et al.
Publicado: (2019)

Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis
por: DONE, Nicolae, et al.
Publicado: (2023)

Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan
por: Matsumoto, Ryuji, et al.
Publicado: (2018)

Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population
por: Wallia, Amisha, et al.
Publicado: (2021)

Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database
por: Liu, Jui-Ming, et al.
Publicado: (2020)

First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study
por: Basile, Debora, et al.
Publicado: (2021)

Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies
por: Gomez-Inhiesto, Elisa, et al.
Publicado: (2020)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Eligibility of real-world patients with metastatic breast cancer for clinical trials
por: Batra, Atul, et al.
Publicado: (2020)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
por: Facchini, Gaetano, et al.
Publicado: (2019)

Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
por: Yamada, Toyohiro, et al.
Publicado: (2022)

Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer
por: Satake, Hironaga, et al.
Publicado: (2022)

Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium
por: Schinzari, Giovanni, et al.
Publicado: (2018)

A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
por: Church, Matt, et al.
Publicado: (2021)

Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
por: Cuker, Adam, et al.
Publicado: (2023)

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer
por: Anton, Angelyn, et al.
Publicado: (2021)

Third-line treatment options in metastatic pancreatic cancer patients: a real-world study
por: Lu, Hong-Rui, et al.
Publicado: (2023)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata
por: Ray, Markqayne, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eesmhcvroiquurucnvo1crog47